Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Yashinsky

Internal Medicine Farmington Hills, MI Doctor of Osteopathy

NPI 1447637681 CMS profile 1334151

30055 Northwestern Hwy Ste 150, Farmington Hills, MI 48334

Open in the dashboard

General payments

$7,453

395 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Yashinsky of Farmington Hills, MI is reported in the CMS Open Payments database as having received $7,453 across 395 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,101 108
2024 General $1,788 96
2023 General $1,566 93
2022 General $738 42
2021 General $152 9
2020 General $17 1
2019 General $1,090 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Yashinsky
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Samuel Yashinsky were reported at $2,101. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Samuel Yashinsky Internal Medicine median Middle half National median
2019 $1,090 $159 $48–$570 $163
2020 $17 $119 $33–$402 $114
2021 $152 $135 $37–$521 $132
2022 $738 $141 $42–$496 $149
2023 $1,566 $149 $45–$519 $160
2024 $1,788 $154 $47–$537 $164
2025 $2,101 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,863 132 payments
  2. AstraZeneca Pharmaceuticals LP $1,187 36 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $450 19 payments
  4. Novartis Pharmaceuticals Corporation $372 19 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $354 20 payments
  6. Amgen Inc. $342 26 payments
  7. AbbVie, Inc. $340 19 payments
  8. Lilly USA, LLC $328 18 payments
  9. Pfizer Inc. $285 15 payments
  10. Sumitomo Pharma America, Inc. $235 7 payments
  11. Other $1,697 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,388 394 payments
  2. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,230 92 payments
  2. RYBELSUS $1,210 84 payments
  3. FARXIGA $469 12 payments
  4. Kerendia $450 19 payments
  5. Wegovy $368 26 payments
  6. BREZTRI $324 12 payments
  7. AIRSUPRA $318 6 payments
  8. Saxenda $265 18 payments
  9. GEMTESA $208 6 payments
  10. QULIPTA $207 12 payments
  11. Other $4,812 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 170 drugs

Part D claims

12,557

Median for Internal Medicine: 777

Drug cost

$1,622,579

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 296 $379,629
Mounjaro Tirzepatide Brand 168 $241,659
Eliquis Apixaban Brand 160 $179,968
Jardiance Empagliflozin Brand 137 $163,056
Trulicity Dulaglutide Brand 69 $81,153
Rybelsus Semaglutide Brand 23 $58,517
Xarelto Rivaroxaban Brand 29 $46,255
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 46 $44,414
Repatha Sureclick Evolocumab Brand 44 $29,080
Entresto Sacubitril/Valsartan Brand 30 $28,872

The 10 drugs with the highest cost, of 170 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$52,620

Medicare's payments for the services billed

Medicare patients

376

Average age 74

Services billed

1,642

192 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 32%
Ischemic heart disease 27%
Chronic kidney disease 17%
Depression 17%
Cancer 16%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $142
$142 23 —
Ozempic
  • Novo Nordisk Inc $142
$142 296 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $120
$120 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $89
$89 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $70
  • Lilly USA, LLC $19
$89 137 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record